Phosphatidylethanolamine at the endothelial surface of aortic flow dividers

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 1, 2009, Pages 227-229

  Li, Z ^a   Wells, C W ^a   Esmon, C T ^b   Zhao, Ming ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; DURAMYCIN; FIBRINOLYTIC AGENT; FLUORESCEIN ISOTHIOCYANATE; GOLD; LIPOCORTIN 5; PHOSPHATIDYLETHANOLAMINE;

ANIMAL TISSUE; AORTA ARCH; AORTA FLOW; AORTA WALL; CONTROLLED STUDY; DRUG PROTEIN BINDING; FIBRINOLYSIS; FLUORESCENCE MICROSCOPY; LETTER; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN LOCALIZATION; RAT; TRANSMISSION ELECTRON MICROSCOPY; VASCULAR ENDOTHELIUM;

ANIMALS; AORTA; BACTERIOCINS; BLOOD FLOW VELOCITY; ENDOTHELIUM, VASCULAR; MICE; MOLECULAR PROBES; PEPTIDES; PHOSPHATIDYLETHANOLAMINES; RATS; REGIONAL BLOOD FLOW;

EID: 57749169060     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03193.x     Document Type: Letter

References (15)

1. Esmon CT. Structure and functions of the endothelial cell protein C receptor. Crit Care Med 2004; 32: S298-301.
2. Esmon CT. The endothelial protein C receptor. Curr Opin Hematol 2006; 13: 382-5.
3. Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-9.
4. Tsuda T, Yoshimura H, Hamasaki N. Effect of phosphatidylcholine, phosphatidylethanolamine and lysophosphatidylcholine on the activated factor X-prothrombin system. Blood Coagul Fibrinolysis 2006; 17: 465-9.
5. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95: 309-16.
6. Sanmarco M, Gayet S, Alessi MC, Audrain M, de Maistre E, Gris JC, de Groot PG, Hachulla E, HarléJR, SiéP, Boffa MC. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost 2007; 97: 949-54.
7. Tian Y, Jackson P, Gunter C, Wang J, Rock CO, Jackowski S. Placental thrombosis and spontaneous fetal death in mice deficient in ethanolamine kinase 2. J Biol Chem 2006; 281: 28438-49.
8. Chandran KB. Flow dynamics in the human aorta. J Biomech Eng 1993; 115: 611-6.
9. Hayashi F, Nagashima K, Terui Y, Kawamura Y, Matsumoto K, Itazaki H. The structure of PA48009: The revised structure of duramycin. J Antibiot 1990; 43: 1421-30.
10. Iwamoto K, Hayakawa T, Murate M, Makino A, Ito K, Fujisawa T, Kobayashi T. Curvature-dependent recognition of ethanolamine phospholipids by duramycin and cinnamycin. Biophys J 2007; 93: 1608-19.
11. Zhao M, Li Z, Bugenhagen S. 99m Tc labeled Duramycin as a novel phosphatidylethanolamine-binding molecular probe. J Nucl Med 2008; 49: 1345-52.
12. Glauert AM. Practical Methods in Electron Microscopy. Amsterdam: North-Holland Pub. Co., 1998.
13. Bevers EM, Comfurius P, Dekkers DW, Zwaal RF. Lipid translocation across the plasma membrane of mammalian cells. Biochim Biophys Acta 1999; 1439: 317-30.
14. Tait JF, Gibson D. Phospholipid binding of annexin V: Effects of calcium and membrane phosphatidylserine content. Arch Biochem Biophys 1992; 298: 187-91.
15. Williamson P, Schlegel RA. Transbilayer phospholipid movement and the clearance of apoptotic cells. Biochim Biophys Acta 2002; 1585: 53-63.